<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <span class="govuk-caption-xl gem-c-title__context">
      Guidance
    </span>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    Guidance on substantial amendments to a clinical trial from 1 January 2021
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph">This guidance covers substantial amendments to a clinical trial including changes to the trial sponsor/legal representative, Investigational medicinal product certification and importation and amendments to the Research Ethics Committee.</p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div class="app-c-publisher-metadata" lang="en">
    <div class="app-c-published-dates " lang="en">
    Published 1 September 2020
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a class="govuk-link" href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>



  <section class="app-c-header-notice" aria-label="notice" role="region">
    <div class="app-c-header-notice__header">
      <h2 class="app-c-header-notice__title">New rules for January 2021</h2>
    </div>

    <div class="app-c-header-notice__content">
          <p class="app-c-header-notice__text govuk-body">The UK has left the EU, and the transition period after Brexit comes to an end this year.</p>
          <p class="app-c-header-notice__text govuk-body">This page tells you what you'll need to do from 1 January 2021. It will be updated if anything changes.</p>
        <div class="app-c-header-notice__links">
            <p class="govuk-body app-c-header-notice__link-intro">
              For current information, read: 
              <a data-module="track-click" data-track-category="no_deal_notice" data-track-action="/government/collections/clinical-trials-for-medicines" data-track-label="Clinical Trials for Medicines" class="app-c-header-notice__link" href="/government/collections/clinical-trials-for-medicines">Clinical Trials for Medicines</a>
            </p>
        </div>

        <p class="app-c-header-notice__text govuk-body">You can also read about <a data-module="track-click" data-track-category="no_deal_notice" data-track-action="/transition" data-track-label="the transition period" class="govuk-link" href="/transition">the transition period</a>.</p>
    </div>
  </section>


<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div id="contents" class="app-c-contents-list-with-body" data-module="sticky-element-container">
      <div class="responsive-bottom-margin">
          <nav class="gem-c-contents-list  gem-c-contents-list--no-underline " role="navigation" data-module="track-click">
      <h2 class="gem-c-contents-list__title">Contents</h2>

    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#changes-to-the-trial-sponsor-legal-representative" data-track-options="{"dimension29":"Changes to the trial sponsor/ legal representative"}" href="#changes-to-the-trial-sponsor-legal-representative">Changes to the trial sponsor/ legal representative</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#investigational-medicinal-product-imp-certification-and-importation" data-track-options="{"dimension29":"Investigational medicinal product (IMP) certification and importation"}" href="#investigational-medicinal-product-imp-certification-and-importation">Investigational medicinal product (IMP) certification and importation</a>

        </li>
    </ol>
</nav>
      </div>
    
      
<div class="gem-c-govspeak govuk-govspeak direction-ltr" data-module="govspeak">
      <div class="govspeak">
<h2 id="changes-to-the-trial-sponsor-legal-representative">Changes to the trial sponsor/ legal representative</h2>

<p>The UK will require the sponsor or legal representative of a clinical trial to be in the UK or country on an approved country list which would initially include EU/European Economic Area (<abbr title="European Economic Area">EEA</abbr>) countries.</p>

<p>A change in sponsor or legal representative for an UK trial is a substantial amendment requiring submission to both MHRA and the Research Ethics Committee (REC).</p>

<h3 id="action-to-take-from-1-january-2021">Action to take from 1 January 2021</h3>
<p>Where the sponsor is from the rest of the world and the legal representative is established in the UK and there are sites elsewhere in the EU/<abbr title="European Economic Area">EEA</abbr>, the sponsor will need to assign an EU/<abbr title="European Economic Area">EEA</abbr> legal representative for these sites via a substantial amendment to the relevant EU/<abbr title="European Economic Area">EEA</abbr> competent authorities.</p>

<p>No amendment submission to MHRA is required where the sponsor or legal representative for an ongoing trial is established in the EU/<abbr title="European Economic Area">EEA</abbr> as the UK will continue to accept this.</p>

<p>No amendment will need to be submitted in the UK if the sponsor retains the UK legal representative for the UK study. Similarly, no amendment will need to be submitted in the UK if a sponsor remains in the UK and a legal representative is added to cover EU/<abbr title="European Economic Area">EEA</abbr> sites.</p>

<h2 id="investigational-medicinal-product-imp-certification-and-importation">Investigational medicinal product (<abbr title="Research Ethics Committee">IMP</abbr>) certification and importation</h2>
<p>As is the case today, a substantial amendment will be required to be submitted to MHRA to change (add/replace) any <abbr title="Research Ethics Committee">IMP</abbr> manufacturing, importation or certification site relevant for supply of <abbr title="Research Ethics Committee">IMP</abbr> to an ongoing UK trial.</p>

<p>If the sponsor chooses to retain an existing UK <abbr title="Research Ethics Committee">IMP</abbr> release site for the ongoing UK trial but includes an additional EU/<abbr title="European Economic Area">EEA</abbr> site for trials in the EU/<abbr title="European Economic Area">EEA</abbr> only, then no substantial amendment to MHRA will be required.</p>

<p>The <abbr title="Research Ethics Committee">IMP</abbr> supply chain from a country on the approved country list which would initially include EU/<abbr title="European Economic Area">EEA</abbr> countries, will allow direct supply to clinical investigator sites.</p>

<h3 id="action-to-take-from-1-january-2021-1">Action to take from 1 January 2021</h3>

<p>If the holder is required to be included for importation to an ongoing trial, a substantial amendment should be submitted to the MHRA to include the details of the <abbr title="Manufacturing and Import Authorisation for Investigational Medicinal Products">MIA(IMP)</abbr> holder performing the ‘supply chain oversight’ role within 1 year of 1 January 2021.</p>

<p>This means that for up to 1 year after 1 January 2021, IMPs may be supplied direct from the EU/<abbr title="European Economic Area">EEA</abbr> <abbr title="Manufacturing and Import Authorisation for Investigational Medicinal Products">MIA(IMP)</abbr> holder to the ongoing Great Britain trial site without the GB MIA (<abbr title="Research Ethics Committee">IMP</abbr>) oversight process.</p>

<h4 id="amendments-relevant-to-the-research-ethics-committee-rec">Amendments relevant to the Research Ethics Committee (REC)</h4>

<p>The Health Research Authority (<abbr title="The Health Research Authority">HRA</abbr>) has produced <a rel="external" href="https://www.hra.nhs.uk/approvals-amendments/" class="govuk-link">guidance on when amendments are required to be submitted for REC review</a>.</p>

<h3 id="northern-ireland-protocol">Northern Ireland Protocol</h3>

<p>Further information on this will be provided in due course.</p>

</div>
</div>


      <div class="responsive-bottom-margin">
        <div class="app-c-published-dates " lang="en">
    Published 1 September 2020
</div>

      </div>

      <div data-sticky-element class="app-c-contents-list-with-body__link-wrapper">
        <div class="app-c-contents-list-with-body__link-container">
          <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" height="17" viewbox="0 0 13 17">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

        </div>
      </div>
  </div>
  </div>
  
<div class="govuk-grid-column-one-third">
  
<div class="gem-c-contextual-sidebar">
    <div class="gem-c-contextual-sidebar__brexit-cta govuk-!-margin-bottom-6" data-module="track-click">
  <h2 class="gem-c-contextual-sidebar__brexit-heading">Transition period</h2>
  <a href="/transition" class="govuk-link" data-track-category="relatedLinkClicked" data-track-action="1.0 Transition" data-track-label="/transition" data-track-options="{"dimension29":"Find out what it means for you"}">Find out what it means for you</a>
</div>



    
  <div class="gem-c-related-navigation">

      <h2 id="related-nav-related_items-c19b5a34" class="gem-c-related-navigation__main-heading" data-track-count="sidebarRelatedItemSection">
        Related content
      </h2>




      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-collections-c19b5a34" data-module="gem-toggle">

    <h3 id="related-nav-collections-c19b5a34" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--sidebar" data-track-count="sidebarRelatedItemSection">Collection</h3>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar" data-track-category="relatedLinkClicked" data-track-action="1.1 Collection" data-track-label="/government/collections/mhra-post-transition-period-information" data-track-options="{"dimension28":"1","dimension29":"MHRA post-transition period information"}" href="/government/collections/mhra-post-transition-period-information">MHRA post-transition period information</a></li>

  </ul>
</nav>

  </div>



</div>

</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-topics-e17f40dc" data-module="gem-toggle">

    <h2 id="related-nav-topics-e17f40dc" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.1 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/manufacturing-wholesaling-importing-exporting-medicines" data-track-options="{"dimension28":"3","dimension29":"Manufacturing, wholesaling, importing and exporting medicines"}" href="/topic/medicines-medical-devices-blood/manufacturing-wholesaling-importing-exporting-medicines">Manufacturing, wholesaling, importing and exporting medicines</a></li>
        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.2 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" data-track-options="{"dimension28":"3","dimension29":"Marketing authorisations, variations and licensing guidance"}" href="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing">Marketing authorisations, variations and licensing guidance</a></li>
        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.3 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/medical-devices-regulation-safety" data-track-options="{"dimension28":"3","dimension29":"Medical devices regulation and safety"}" href="/topic/medicines-medical-devices-blood/medical-devices-regulation-safety">Medical devices regulation and safety</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>